Chronic Kidney Disease
Conditions
Keywords
Abelmoschus manihot, Chronic Kidney Disease, proteinuria, efficacy, safety
Brief summary
Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease. The purpose of this study is to evaluate the safety and efficacy of Abelmoschus manihot for treating chronic kidney disease in large scale samples with long time take.
Detailed description
The test has not been completed.
Interventions
DRUGAbelmoschus manihot (AM)
Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
Sponsors
Jiangsu Suzhong Pharmaceutical Group Co., Ltd.
Chinese PLA General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosed as non-ESRD chronic kidney disease (stage I-IV) * Blood pressure of ≤140/90mmHg * Obtaining the signed informed consent from patients
Exclusion criteria
* Be allergic to Huangkui Capsule * Combined with severe primary diseases of heart, brain, liver and hematopoietic system and so on, or other serious diseases which can affect the patient's life * Lactation, pregnancy or plans pregnancy during the study period * Participating in another clinical study in the same period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in 24-h proteinuria from baseline after treatment | Baseline(week 0), week 12, week 24 |
Secondary
| Measure | Time frame |
|---|---|
| change in the serum creatinine level from baseline after treatment | Baseline(week 0), week 12, week 24 |
| change in the estimated glomerular filtration rate (eGFR) from baseline after treatment | Baseline(week 0), week 12, week 24 |
Countries
China
Outcome results
None listed